Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson nears diabetes device exit with $2.1 billion LifeScan sale

03/16/2018 | 10:12am EDT
A Johnson & Johnson building is shown in Irvine, California

(Reuters) - Johnson & Johnson said on Friday it was offered about $2.1 billion for its LifeScan Inc unit, which makes blood glucose monitoring products, by private equity firm Platinum Equity, another step towards exiting the diabetes device market.

(Reuters) - Johnson & Johnson said on Friday it was offered about $2.1 billion for its LifeScan Inc unit, which makes blood glucose monitoring products, by private equity firm Platinum Equity, another step towards exiting the diabetes device market.

Platinum has given J&J until mid-June to accept the offer to allow for consultations with overseas workers.

Sales at J&J's diabetes device business, which also includes Animas Corp and Calibra Medical Inc, have been falling since 2012 in a highly competitive market and the company said last January that it was evaluating options for the units.

J&J said in October it would shut down Animas, which makes insulin pumps, after failing to find a buyer. J&J spokeswoman Donna Lorenson said the strategic review of the Calibra division, which sells wearable insulin pumps, is ongoing.

LifeScan, which has headquarters in Chesterbrook, Pennsylvania, and Zug, Switzerland, sells personal blood glucose meters, testing strips, and testing systems. More than 20 million people in 90 countries use its products.

Platinum Equity said in a press release that it is currently consulting with works councils that represent employees. The offer could be finalized by mid-June, unless it is extended, and a deal is anticipated to close by the end of 2018.

The company has 2,400 employees, largely in Europe, China and the United States, Lorenson said.


The price for LifeScan, which generated revenue of about $1.5 billion in 2017, was disappointing but fair since the unit had weighed on J&J's growth for some time, Atlantic Equities analyst Steve Chesney said.

"Obviously expectations were for a higher valuation based on earlier reports, but probably closer to reality given the state of the business," Chesney said.

Reuters had reported in January that Chinese buyers were interested in paying $3 billion to $4 billion for the companies.

Cowen analyst Joshua Jennings said in a research note that the LifeScan valuation was reasonable given that the business was declining and facing continued pricing pressure.

J&J said it factored the transaction into the 2018 earnings forecast it gave in January.

J&J shares fell 0.4 percent, or 56 cents, to $132.50 in morning trading.

(Reporting by Arjun Panchadar and Munsif Vengattil in Bengaluru, additional reporting by Caroline Humer in New York; Editing by Savio D'Souza and Phil Berlowitz)

By Arjun Panchadar

ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.46% 172.66 Delayed Quote.9.71%
ONE STOP SYSTEMS, INC. -1.34% 5.14 Delayed Quote.28.50%
STEP CO.,LTD. -0.28% 1810 End-of-day quote.13.34%
All news about JOHNSON & JOHNSON
07/27JOHNSON & JOHNSON : to Participate in the Virtual Wells Fargo Healthcare Confere..
07/27JOHNSON & JOHNSON : Single-Shot COVID-19 Vaccinations to Resume in the U.S. for ..
07/27JOHNSON & JOHNSON : Mozambique to Vaccinate 20 Per Cent of Its Target By Septemb..
07/26ASPEN PHARMACARE : To Send First Batch Of Johnson & Johnson Jab To South Africa ..
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $1..
07/23ASTRAZENECA : EU On Track To Donate 200 Million COVID-19 Vaccine Doses In 2021
07/22JOHNSON & JOHNSON : Opioid-ravaged West Virginia looks to $26B deal for help
07/22JOHNSON & JOHNSON : In opioid-ravaged WVa, potential deal raises hopes for help
More news
Financials (USD)
Sales 2021 94 452 M - -
Net income 2021 22 808 M - -
Net cash 2021 471 M - -
P/E ratio 2021 20,3x
Yield 2021 2,40%
Capitalization 455 B 455 B -
EV / Sales 2021 4,81x
EV / Sales 2022 4,58x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 172,66 $
Average target price 184,35 $
Spread / Average Target 6,77%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.71%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.14.37%234 040
NOVARTIS AG-0.17%221 954
ABBVIE INC.10.09%208 043